|
SLS | Sellas Life Sciences Group, Inc. |
|
|
SLS | Sellas Life Sciences Group, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.82 |
| Leverage | 11.49% |
| Market Cap | $ 55.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -25.9m |
| Margin | -2607.41% |
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.